Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Net Cash Flow (2019 - 2025)

Historic Net Cash Flow for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to $168.5 million.

  • Nurix Therapeutics' Net Cash Flow rose 143859.22% to $168.5 million in Q4 2025 from the same period last year, while for Nov 2025 it was $137.0 million, marking a year-over-year increase of 14748.06%. This contributed to the annual value of $137.0 million for FY2025, which is 14748.06% up from last year.
  • According to the latest figures from Q4 2025, Nurix Therapeutics' Net Cash Flow is $168.5 million, which was up 143859.22% from -$5.8 million recorded in Q3 2025.
  • Nurix Therapeutics' Net Cash Flow's 5-year high stood at $168.5 million during Q4 2025, with a 5-year trough of -$66.9 million in Q4 2021.
  • Over the past 5 years, Nurix Therapeutics' median Net Cash Flow value was $2.5 million (recorded in 2022), while the average stood at $6.4 million.
  • Per our database at Business Quant, Nurix Therapeutics' Net Cash Flow plummeted by 268154.82% in 2023 and then soared by 143859.22% in 2025.
  • Nurix Therapeutics' Net Cash Flow (Quarter) stood at -$66.9 million in 2021, then skyrocketed by 125.28% to $16.9 million in 2022, then dropped by 27.16% to $12.3 million in 2023, then dropped by 11.12% to $11.0 million in 2024, then surged by 1438.59% to $168.5 million in 2025.
  • Its Net Cash Flow stands at $168.5 million for Q4 2025, versus -$5.8 million for Q3 2025 and $8.3 million for Q2 2025.